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Patients with neurofibromatosis-1 (NF-1) sometime develop neuroendocrine tumors (NET). Although these NETs
usually occur in the duodenum or peri-ampullary region, they occasionally grow in the pancreas (PNET). A
62-year-old man with NF-1 had mild liver dysfunction and was admitted to our hospital for further examination. An
abdominal contrast-enhanced computed tomography scan demonstrated a 30-mm tumor in the head of the
pancreas. The scan showed an invasion of the tumor into the duodenum, and biopsy under an endoscopic
ultrasonography indicated that the tumor was a NET. A subtotal stomach-preserving pancreaticoduodenectomy
was performed. Macroscopically, the pancreatic tumor was white and elastic hard. Microscopically, tumor cells were
composed of ribbons, cords, and solid nests with an acinus-like structure. The tumor was diagnosed as NET G2
according to the WHO classification (2010). The product of theNF-1 gene, i.e., neurofibromin, was weakly positive in
the tumor cells, suggesting that the tumor was induced by a mutation in the NF-1 gene. This is the seventh case of
PNET arising in NF-1 patients worldwide.
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Neurofibromatosis-1 (NF-1), known as von Recklinghausen’s
disease, is an autosomal dominant, multisystem disorder
that occurs in 1 in 2,500–3,000 live births [1,2]. This heredi-
tary disorder is characterized by pigmentary features (café-
au-lait macules, skinfold freckling), neurofibroma, ortho-
pedic features (scoliosis, dysplasia of a long bone), and
ophthalmologic features (Lisch nodules, optic glioma) [1-3].
The NF-1 gene is located on chromosome 17q11.2,
and encodes the protein neurofibromin [4,5]. Neurofi-
bromin is a tumor suppressor expressed in many cells,
so NF-1 gene mutation leads to uncontrolled cell prolif-
eration and development of benign and malignant
tumors, including neuroendocrine tumors (NETs) [1,3].
The most frequent target organ of NETs in patients with
NF-1 is the duodenum and peri-ampullary region [6-9].
Pancreatic NETs (PNETs) sometimes occur in hereditary
diseases, such as multiple endocrine neoplasia type 1* Correspondence: nishiken@med.shimane-.ac.jp
1Department of Digestive and General Surgery, Shimane University Faculty of
Medicine, 89-1 Enyacho, Izumo 693-8501 Shimane, Japan
Full list of author information is available at the end of the article
© 2012 Nishi et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(MEN-1) and von Hippel-Lindau disease (VHL), but
they rarely develop in patients with NF-1 [10,11]. Only
six cases of PNETs, including four malignant cases of
PNETs, have previously been reported in patients with
NF-1 [12-17]. Here, we report a rare case of PNET aris-
ing in a patient with NF-1.Case presentation
A 62-year-old man with NF-1 had mild liver dysfunction
diagnosed by medical examination, and he was admitted
to our hospital for further examination. In his past his-
tory, he had developed blindness in childhood because
of pigmentary retinal dystrophy. There was no history of
hypoglycemia or peptic ulcer. On admission, he had no
clinical symptoms. His height was 141 cm and his body
weight was 52 kg. Numerous café-au-lait macules and
cutaneous neurofibromas were noted over his whole
body (Figure 1). There were no palpable lymph nodes in
the surface or mass lesions in the abdomen. The
patient’s blood pressure was 112/70 mmHg and heart
rate was 72 beats per min without abnormality on
electrocardiogram examination. Alkaline phosphatase,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A view of the back of the patient. Numerous café-au-lait
macules and cutaneous neurofibromas can be seen.
a
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levels were slightly elevated; other biochemical data, in-
cluding tumor markers, were almost within the normal
ranges. Values for fasting plasma glucose, hemoglobin
A1c, and serum glucagon were within the normal limits,
but the serum gastrin level was slightly higher than the
normal upper limit. Upper gastrointestinal endoscopy
showed a reddish, chorioepithelial hyperplasia of the sec-
ond part of the duodenum. A biopsy specimen of the le-
sion revealed hyperplasia of Brunner’s glands. There
was no peptic ulcer in the stomach and duodenum. Col-
onoscopy showed no abnormality. An abdominal
contrast-enhanced computed tomography (CT) scan
demonstrated a low-attenuating tumor in the head of
the pancreas, measuring 30 mm in diameter, with slow
enhancement (Figure 2). The upper common bile ductFigure 2 Findings of an abdominal contrast-enhanced
computed tomography scan. The scan demonstrates a 30-mm
tumor in the head of the pancreas (arrow), with slow enhancement.was extended, but the main pancreatic duct was not
dilated. Some lymph nodes around the hepatic hilum
were swollen, with a maximal diameter of 25 mm. No
tumor was detected in the liver and lung, or in the pitu-
itary and parathyroid glands. Endoscopic retrograde cho-
langiopancreatography (ERCP) showed that the lower
common bile duct and main pancreatic duct were
oppressed without any encroachment. Endoscopic ultra-
sonography (EUS) showed a low echoic tumor, measur-
ing 35 mm in diameter, near the papilla of Vater,
compressing both the common bile duct and main pan-
creatic duct. The lesion continued to the fourth layer of
the duodenal wall. Swollen lymph nodes were detected
near the common bile duct. Fine-needle aspiration
biopsy under EUS revealed that the pancreatic mass
was a neuroendocrine tumor, compatible with a
diagnosis of PNET. A subtotal stomach-preserving pan-
creaticoduodenectomy was performed. At laparotomy,
there was no fluid collection, peritoneal dissemination,
or liver metastasis. Because we found two small nodules
in the jejunum and one small nodule in the stomach,b
Figure 3 Macroscopic findings of the pancreatic tumor. (a) The
tumor showed an invasion into the duodenal mucosa (arrow). (b) A white
and elastic hard tumor, 30×35×40 mm in size, was located in the head










Figure 4 Microscopic findings of the pancreatic tumor. (a) Tumor cells were composed of ribbons, cords, and solid nests with acinus-like
structure (hematoxylin and eosin, magnification 200×). (b) Hyperplasia of islet cells (positive for chromogranin A staining) was frequently found in
the non-neoplastic pancreas (chromogranin A staining, magnification 140×). (c,d,e) Expression of chromogranin A, synaptophysin, and CD56 was
strongly positive in the tumor cells (c: chromogranin A staining, magnification 400×; d: synaptophysin staining, magnification 400×; e: CD56
staining, magnification 400×). (f/g) Some of tumor cells, particularly in the acinus-like structure, were positive for α1-antichymotrypsin and
α1-antitrypsin (f: α1-antichymotrypsin staining, magnification 400×/g: α1-antitrypsin staining, magnification 400×). (h) Expression of neurofibromin
was negative in the tumor cells (neurofibromin staining, magnification 400×). (i) Pancreatic islet cells in the non-neoplastic region demonstrated a
strongly positive expression of neurofibromin (arrow). Acinar cells and ductal epithelial cells showed negative expression of neurofibromin
(neurofibromin staining, magnification 400×).
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Table 1 List of antibodies for immunohistochemical
examination
Antibody Source
Chromogranin A Rabbit polyclonal antibody
Synaptophysin Mouse monoclonal antibody
CD56 Mouse monoclonal antibody
α1-Antichymotrypsin Rabbit polyclonal antibody
α1-Antitrypsin Rabbit polyclonal antibody
Neurofibromin Mouse monoclonal antibody
Ki-67 Mouse monoclonal antibody
c-kit Rabbit polyclonal antibody
CD34 Mouse monoclonal antibody
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performed.
Macroscopically, a white and elastic hard tumor,
30 × 35 × 40 mm in size, was identified in the head of the
pancreas, and it had invaded the duodenum (Figure 3).
Microscopically, tumor cells were composed of ribbons,
cords, and solid nests with an acinus-like structure
(Figure 4a). Tumor cells were considered to have islet
cell origin because they had uniform nuclei with a salt-
and-pepper appearance, and hyperplasia of islet cells was
frequently found in the non-neoplastic pancreas
(Figure 4b). On the other side, in the part of acinus-like
pattern mimicking normal acinar cells, cytoplasms of
these cells were eosinophilic and granular, associated
with zymogen granules, which were positive for α-
antitrypsin and α-antichymotrypsin. These tumor cells
were smaller than formerly, and sometimes vacuolar
changes could be observed. A pattern of transmigration
into normal acinar cells was shown; thus, the tumor sug-
gested including an exocrine-derived component. On
immunohistochemical examination (all antibodies for
immunohistochemical examination were listed on
Table 1), neuroendocrine tumor markers, such as chro-
mogranin A, synaptophysin, and CD56, were positive
(Figure 4c/d/e). Some of the tumor cells, particularly in
the acinus-like structure, were also positive for α1-Table 2 Pancreatic neuroendocrine tumors in patients with n
Authors [ref.] Year Sex Age (years) Site o
Coskey and Tranquanda [12] 1964 Female 66 Body a
Saurenmann et al. [13] 1987 Male 62 Head
Fung and Lam [14] 1995 Male 45 Body a
Thannberger et al. [15] 2001 Male 28 Head
Fujisawa et al. [16] 2002 Female 66 Head
Perren et al. [17] 2006 ND ND Body
Nishi et al. (present case) Male 62 Head
*These cases were reported before 2010, so it is difficult to apply the new WHO cla
adenocarcinoma in the previous WHO classification (2000). We listed our tumor as mantichymotrypsin and α1-antitrypsin (Figure 4f/g). Neu-
rofibromin protein expression was negative in the tumor
cells (Figure 4h), in contrast being strongly positive in is-
lets in the non-neoplastic pancreas (Figure 4i). Accord-
ing to the WHO classification (2010), the tumor was
diagnosed as “neuroendocrine tumor, NET G2,” because
the Mib1 index (%) is 7% and proliferation rate is 4 mi-
toses per 10HPF [18],and the tumor was composed aci-
nar and neuroendocrine cells. The acinar component
was about 15% and neuroendocrine component about
55%; cells with both characterscomprised about 30%.
According to the TNM classification [19], the tumor was
classified as pT3N1M0, G2, R0, stage IIB. The tumors of
the jejunum and stomach were compatible with a diag-
nosis of gastrointestinal stromal tumor (GIST) present-
ing with positive expression for c-Kit and CD34 on
immunohistochemistry. The patient received adjuvant
chemotherapy with TS-1 for 1 year. At follow-up 2 years
after surgery, the patient remained well without any re-
current pancreatic disease.
Conclusions
Only 1–2% of cases of PNETs occur as part of an inher-
ited disorder, such as MEN-1, VHL, tuberous sclerosis
complex (TSC), and NF-1 [10,11]. The frequency of
PNETs with hereditary disease is high in the order of
MEN1, VHL, NF-1 and TSC [10]. In patients with NF-1,
neuroendocrine tumors sometimes develop: the most
common tumor is somatostatinoma arising in the peri-
ampullary and duodenal region [6,8,9]. PNET with NF-1
is rare and, to our knowledge, only six cases of PNETs
with NF-1 have previously been reported (Table 2)
[12-17].
Neurofibromin, the product of the NF-1 gene, acts as
a tumor suppressor because it inhibits the activity of ras
guanosine triphosphatase-activating protein, which regu-
lates cell proliferation and differentiation [2,3]. Mutation
of the NF-1 gene and dysfunction of neurofibromin lead
to uncontrolled cell proliferation and development of
some tumors, including neurofibroma, glomus tumor,
carcinoid tumor, and gastrointestinal tumor. The rarityeurofibromatosis-1
f tumor in pancreas Histology Malignant*
nd tail Insulinoma Yes
Somatostatinoma No




Neuroendocrine tumor, NET G2 Yes
ssification (2010). Although our case is NET G2, NET G2 was well-differentiated
alignant according to the previous diagnosis to check with other cases.
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occurs coincidentally or because of NF-1 gene mutation.
Perren et al. [17] reported that neurofibromin expression
was negative in an insulinoma of the pancreas in a pa-
tient with NF-1, but that neurofibromin expression was
strongly positive in a sporadic insulinoma on immuno-
histochemistry; in addition, neurofibromin expression
was reduced at the mRNA level in the insulinoma of the
pancreas in a patient with NF-1. Thus, they concluded
that their case was a result of an NF-1 gene mutation.
Furthermore, Speel et al. [20] analyzed genetic differ-
ences in PNETs and found that no sporadic tumors had
a loss of heterozygosity in 17q, which encodes the NF-1
gene. These results indicate that PNET in patients with
NF-1 might be induced by the NF-1 gene mutation. In
our case, the PNET was negative for neurofibromin, sug-
gesting a decrease in neurofibromin expression asso-
ciated with NF-1 gene mutation. In addition, in our case,
hyperplasia of islet cells occurred frequently in the non-
neoplastic pancreas, which is a very unusual finding in
normal NETs. This suggested that the islet cells in our
patient had a tendency to develop hyperplasia frequently,
and this may have developed into an endocrine
carcinomatumor.
GISTs in the jejunum and stomach were found inci-
dentally during surgery in our patient. A high incidence
of GIST arising in patients with NF-1 has been reported
previously [21]. In addition, GISTs in patients with NF-1
often develop in the small intestine, and multiple occur-
rence is common, while it is rare in sporadic GISTs [21].
Furthermore, coincidental development of GIST and
NET has been recognized, particularly in patients with
NF-1 [22]. Recently, Yamamoto et al. [23] reported that
KIT and platelet-derived growth factor receptor-alpha
(PDGFRA) mutations are very rare events in NF-1 GIST
and that activation of the RAS-MAPK pathway asso-
ciated with inactivation of the NF-1 gene may play an
important role in the development of GIST in NF-1
patients.
NF-1 is also associated with various benign and malig-
nant neoplasms, including tumors of the nervous system
and gastrointestinal tract. The main cause of death in
patients with NF-1 is malignant nerve sheath tumor
[24]. Our patient had a PNET (G2) and multiple GISTs,
as well as subcutaneous neurofibromas; pancreatic endo-
crine carcinoma was considered to be the most life-
threatening tumor. Of the six reported cases of PNET
with NF-1, four were malignant. These cases were
reported before 2010, so it is difficult to apply the new
WHO classification(2010),although the case reported as
carcinoma seems to have malignant features, and is con-
sidered NET G2 or NEC. On the other hand, Relles
et al. [9] demonstrated that only 1% of peri-ampullary
and duodenal NETs in patients with NF-1 weremalignant. Therefore, PNET with NF-1 seems to include
a great potential for malignancy, and there might be
some differences in tumorigenesis between peri-
ampullary NETs and PNETs in NF-1 patients. Although
our patient remained well without any recurrent pancre-
atic disease at follow-up 2 years after surgery, careful ob-
servation is required.
In summary, PNET arising in patients with NF-1 is a
rare occurrence and has the potential to be highly malig-
nant. Although mutation of the NF-1 gene and dysfunc-
tion of neurofibromin may affect on the development of
PNET in patients with NF-1, further investigation is
required to clarify this association.
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